Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Immunotherapy sensitive advanced or metastatic cancer Clinical criteria: Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for the condition which treatment was commenced for. The stated maximum amount in this listing is 360 mg however alternative dosing schedules may be prescribed in a quantity up to this amount, but need not be this amount for every cancer type.
Stage III melanoma Clinical criteria: Patient must not have received prior PBS-subsidised treatment for this condition, AND The treatment must be in addition to complete surgical resection, AND Patient must have a WHO performance status of 1 or less, AND The treatment must be in combination with PBS-subsidised treatment with nivolumab. Prescribed amounts must be consistent with the treatment protocol used for an individual patient. When ipilimumab is initially prescribed as a 3-weekly dosing regimen, patients must only receive a maximum of 80 mg every 3 weeks for 2 cycles (i.e., 1 repeat), in combination with nivolumab.
“Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells.”
“15 days”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.